- Innovent declares Phase 3 success for ADC that attracted huge Takeda dealInnovent Biologics' ADC candidate has passed a Phase 3 trial in advanced stomach cancer and is under priority review in China, but details of the success are still under wraps. The Phase 3 win will…Endpoints · 1mo ago↗ source
- Fulcrum lays off majority of staff; Seres extends runway into 2027👥 Fulcrum Therapeutics reduced to a shell: The biotech is letting go 48 of its 57 full-time employees, according to an SEC filing. The step comes after Fulcrum saidEndpoints · 1mo ago↗ source
- Novo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial execUli Stilz has been trotting the globe this year to talk about the future of biotech and bridge an increasingly international industry. He was in Japan this week,